blood product-associated infection

Illustration(s) pertain to the topic addressed in this publication, not the specific research or data presented in the publication

Absence of human T-cell lymphotropic virus type I coinfection in human immunodeficiency virus-infected hemophilic men

by

Abstract

Concern for transmission of human T-cell lymphotropic virus, type 1 (HTLV-1) infection to recipients of infected cellular blood products has prompted development of tests to eliminate blood units with HTLV-I antibodies. Most hemophilic men from the United States became infected with human immunodeficiency virus (HIV) before HIV donor screening and before blood products were processed to inactivate the virus.… Read more

Illustration(s) pertain to the topic addressed in this publication, not the specific research or data presented in the publication

HTLV I/II and HTLV III seroprevalence in blood product recipients

by

Abstract

Human T-cell leukemia virus type I (HTLV-I) has been strongly implicated as the etiology of adult T-cell leukemia (ATL), a T-cell type non-Hodgkin’s lymphoma with leukemic manifestations in Japan, the Caribbean, and the southeastern United States. The prevalence of serum antibody specific for one core antigen of HTLV-I, p24, has been found to be high in patients with ATL, and higher in relatives of these patients than in general population controls.… Read more

Illustration(s) pertain to the topic addressed in this publication, not the specific research or data presented in the publication

Human T-cell leukemia virus (HTLV-I) p24 antibody in New York City blood product recipients

by

Abstract

Human T-cell leukemia virus (HTLV-I)

is known to be associated with certain hematologic malignancies, and a related virus, HTLV-III/LAV, might be the cause of AIDS. Some persons with AIDS have had evidence of HTLV-I infection. Unrelated to these findings, it has been suggested that HTLV-I is transmitted via blood products.… Read more

Illustration(s) pertain to the topic addressed in this publication, not the specific research or data presented in the publication

Lymphadenopathy-associated virus antibodies and T cells in hemophiliacs treated with cryoprecipitate or concentrate

by

Abstract

Evidence for exposure to lymphadenopathy-associated virus (LAV) was investigated in 48 patients with hemophilia, 15 of whom had been treated exclusively with single-donor cryoprecipitate. The prevalence of antibodies to LAV in all patients was 53% in 1983 and 63% in 1984, while in patients treated only with cryoprecipitate, the prevalence was 31% in 1983 and 40% in 1984.… Read more

Illustration(s) pertain to the topic addressed in this publication, not the specific research or data presented in the publication

HTLV-III/LAV antibody status of spouses and household contacts assisting in home infusion of hemophilia patients

by

Abstract

Thirty-four adult and pediatric hemophilia A and B patients and 50 nonhemophilic members belonging to 28 families were enrolled in August 1984 in a study of human T cell lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) antibody status and T cell subpopulation numbers.… Read more

Illustration(s) pertain to the topic addressed in this publication, not the specific research or data presented in the publication

Human T-lymphotropic retrovirus type III/lymphadenopathy-associated virus antibody. Association with hemophiliacs’ immune status and blood component usage

by

Abstract

We studied the human T-lymphotropic retrovirus type III/lymphadenopathy-associated virus (HTLV-III/LAV) antibody status of 234 factor VIII concentrate recipients, 36 factor IX concentrate recipients, 69 long-term recipients of frozen packed red blood cells, and 47 persons not receiving routine transfusion therapy.… Read more

Illustration(s) pertain to the topic addressed in this publication, not the specific research or data presented in the publication

HTLV-I antibody status in hemophilia patients treated with factor concentrates prepared from U.S. plasma sources and in hemophilia patients with AIDS

by

Abstract

Serum samples from 85 Austrian hemophilia patients treated with lyophilized factor concentrates prepared from U.S. plasma sources, 24 hemophilia patients from Georgia on a home therapy program with factor concentrates, and 10 U.S. hemophilia patients with acquired immunodeficiency syndrome (AIDS) were analyzed by two different methods for the presence of antibodies to the major internal antigen of human T-cell leukemia virus I (HTLV-I) p24.… Read more

Illustration(s) pertain to the topic addressed in this publication, not the specific research or data presented in the publication

Immune status of blood product recipients

by

Abstract

Persons with hemophilia are at risk of the acquired immunodeficiency syndrome (AIDS), and clinically asymptomatic hemophiliacs have shown a high incidence of AIDS-like immune abnormalities, facts leading to speculation that many hemophiliacs have been exposed to the AIDS agent through their blood products.… Read more

Illustration(s) pertain to the topic addressed in this publication, not the specific research or data presented in the publication

Acquired immunodeficiency syndrome (AIDS) in hemophiliacs

by

Abstract

From mid-1977 to mid-1983 the Centers for Disease Control (CDC) has received reports of more than 2,100 cases of acquired immunodeficiency syndrome (AIDS). These cases had either biopsy-confirmed Kaposi’s sarcoma or a biopsy or culture confirmed life-threatening opportunistic infection, without an identifiable cause of immunosuppression.… Read more

Illustration(s) pertain to the topic addressed in this publication, not the specific research or data presented in the publication

Acquired immunodeficiency syndrome (AIDS) associated with transfusions

by

Abstract

Of 2157 patients with the acquired immunode­ficiency syndrome (AIDS) whose cases were reported to the Centers for Disease Control by August 22, 1983, 64 (3 per cent) with AIDS and Pneumocystis carinii pneumonia had no recognized risk factors for AIDS.… Read more